Clinical Trial

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

Study acronym: APPLE TREE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-12.
Trial Details
NCT Number NCT06642272
Lead Sponsor Herlev and Gentofte Hospital
Conditions Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
Enrollment 17,200 participants
Start Date 2024-10-10
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-05